Core Viewpoint - The stock of He Yu-B (02256) has seen a significant increase of over 8%, currently trading at 19.4 HKD, driven by positive market sentiment regarding its drug development [1] Group 1: Company Performance - He Yu-B's drug, Pimitinib, is recognized as the most effective CSF-1R small molecule globally and is set to launch in both China and the U.S., which will provide the company with ongoing sales revenue sharing [1] - The stock's trading volume reached 58.4651 million HKD, indicating strong investor interest [1] Group 2: Market Expectations - According to a report from China Merchants Securities International, Merck has high expectations for Pimitinib, with potential peak sales revenue approaching 1.5 billion USD globally [1] - Citigroup previously noted that the company's valuation reflects only the value of its two late-stage drug candidates, Pimitinib and Ipatasertib, suggesting that the market has not fully recognized the high licensing potential of its differentiated innovative drugs [1]
港股异动 | 和誉-B(02256)涨超8%创历史新高 匹米替尼即将上市 有望给公司带来持续销售分成